What is Auxilius?
Founded in 2020, Auxilius provides a specialized software platform designed to automate and streamline financial operations for biotech and pharmaceutical companies. The platform serves as a centralized hub that integrates real-time clinical data, vendor invoices, and budgetary inputs to replace manual spreadsheet management with automated expense accruals and forecasting. By offering investigator spend intelligence and site payment reconciliation, the company enables finance and clinical operations teams to enhance forecast accuracy and maintain audit readiness. Auxilius distinguishes itself by pairing its purpose-built technology with a dedicated team of finance professionals and auditors, ensuring that its software integrates seamlessly with existing enterprise resource planning and clinical trial management systems.
How much funding has Auxilius raised?
Auxilius has raised a total of $20M across 2 funding rounds:
Series A
$10M
Other Financing Round
$10M
Series A (2022): $10M with participation from Bain Capital Ventures, Renegade Partners, and XYZ Venture Capital
Other Financing Round (2024): $10M led by SignalFire
Key Investors in Auxilius
Bain Capital Ventures
A prominent venture capital firm managing significant committed capital, focusing on early-stage investments across diverse sectors including enterprise software and fintech.
Renegade Partners
A high-conviction venture firm that provides bespoke support and capital to early-stage founders, specifically targeting the transition from startup to enduring company.
SignalFire
A technology-driven venture capital firm that leverages proprietary AI platforms and data-centric insights to ignite growth for early-stage teams in healthtech and enterprise sectors.
What's next for Auxilius?
With this major enterprise-level funding, Auxilius is well-positioned to accelerate its market penetration and deepen its product capabilities. The company's trajectory suggests a focus on scaling its operations to support a growing roster of over 65 biopharmaceutical clients. As the industry faces increasing pressure to optimize R&D spend and improve financial transparency, Auxilius is likely to expand its suite of compliance and risk management tools. The strategic support from its investor base will be instrumental in navigating the transition from a high-growth startup to an essential enterprise utility within the global life sciences ecosystem.
See full Auxilius company page
